560 related articles for article (PubMed ID: 34073174)
21. Daily activity, mood, and quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy: A mediation effect analysis.
Lu LC; Tsay SL; Chang SY; Chen CM; Liu CY
Cancer Med; 2019 Mar; 8(3):963-971. PubMed ID: 30741481
[TBL] [Abstract][Full Text] [Related]
22. Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use.
Li T; Park SB; Battaglini E; King MT; Kiernan MC; Goldstein D; Rutherford C
Qual Life Res; 2022 Nov; 31(11):3091-3107. PubMed ID: 35596913
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
Zhi WI; Chen P; Kwon A; Chen C; Harte SE; Piulson L; Li S; Patil S; Mao JJ; Bao T
Breast Cancer Res Treat; 2019 Dec; 178(3):587-595. PubMed ID: 31456070
[TBL] [Abstract][Full Text] [Related]
24. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes.
Battaglini E; Goldstein D; Grimison P; McCullough S; Mendoza-Jones P; Park SB
J Natl Compr Canc Netw; 2021 Jul; 19(7):821-828. PubMed ID: 34340206
[TBL] [Abstract][Full Text] [Related]
26. Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties.
Griffith KA; Merkies IS; Hill EE; Cornblath DR
J Peripher Nerv Syst; 2010 Dec; 15(4):314-25. PubMed ID: 21199103
[TBL] [Abstract][Full Text] [Related]
27. Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life.
Balayssac D; Kerckhove N; Selvy M; Pereira B; Gonneau C; Pétorin C; Vimal-Baguet A; Melnikov S; Kullab S; Hebbar M; Bouché O; Slimano F; Bourgeois V; Lebrun-Ly V; Thuillier F; Mazard T; Tavan D; Benmammar KE; Monange B; Ramdani M; Péré-Vergé D; Huet-Penz F; Bedjaoui A; Genty F; Leyronnas C; Pezet D; Martin V
Support Care Cancer; 2024 Jun; 32(7):427. PubMed ID: 38869647
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment.
Zanville NR; Nudelman KN; Smith DJ; Von Ah D; McDonald BC; Champion VL; Saykin AJ
Support Care Cancer; 2016 Nov; 24(11):4779-89. PubMed ID: 27470258
[TBL] [Abstract][Full Text] [Related]
29. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
[TBL] [Abstract][Full Text] [Related]
30. Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy.
de Jong C; Herder GJM; van Haarlem SWA; van der Meer FS; van Lindert ASR; Ten Heuvel A; Brouwer J; Egberts TCG; Deneer VHM
Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672910
[TBL] [Abstract][Full Text] [Related]
31. Impact of Somatic Yoga and Meditation on Fall Risk, Function, and Quality of Life for Chemotherapy-Induced Peripheral Neuropathy Syndrome in Cancer Survivors.
Galantino ML; Tiger R; Brooks J; Jang S; Wilson K
Integr Cancer Ther; 2019; 18():1534735419850627. PubMed ID: 31131640
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives.
Ewertz M; Qvortrup C; Eckhoff L
Acta Oncol; 2015 May; 54(5):587-91. PubMed ID: 25751757
[TBL] [Abstract][Full Text] [Related]
33. Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time.
Wang M; Cheng HL; Lopez V; Sundar R; Yorke J; Molassiotis A
BMC Cancer; 2019 Nov; 19(1):1151. PubMed ID: 31775665
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy-Induced Peripheral Neuropathy Assessment Tools: A Systematic Review.
Haryani H; Fetzer SJ; Wu CL; Hsu YY
Oncol Nurs Forum; 2017 May; 44(3):E111-E123. PubMed ID: 28635977
[TBL] [Abstract][Full Text] [Related]
35. Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity.
Alberti P; Bernasconi DP; Cornblath DR; Merkies ISJ; Park SB; Velasco R; Bruna J; Psimaras D; Koeppen S; Pace A; Dorsey SG; Argyriou AA; Kalofonos HP; Briani C; Schenone A; Faber CG; Mazzeo A; Grisold W; Valsecchi M; Cavaletti G;
Neurology; 2021 Aug; 97(7):e660-e672. PubMed ID: 34078718
[TBL] [Abstract][Full Text] [Related]
36. Physical function as a predictor of chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.
Lin KY; Chen PS; Lin CF
BMC Gastroenterol; 2024 May; 24(1):154. PubMed ID: 38711006
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy-Induced Peripheral Neuropathy (CIPN) as a Predictor of Decreased Quality of Life in Testicular Germ Cell Tumor Survivors.
Orszaghova Z; Galikova D; Lesko P; Obertova J; Rejlekova K; Sycova-Mila Z; Palacka P; Kalavska K; Svetlovska D; Mladosievicova B; Mardiak J; Mego M; Chovanec M
Clin Genitourin Cancer; 2024 Jun; 22(3):102067. PubMed ID: 38555680
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review.
Mols F; Beijers T; Vreugdenhil G; van de Poll-Franse L
Support Care Cancer; 2014 Aug; 22(8):2261-9. PubMed ID: 24789421
[TBL] [Abstract][Full Text] [Related]
39. Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).
Kuroi K; Shimozuma K; Ohashi Y; Hisamatsu K; Masuda N; Takeuchi A; Aranishi T; Morita S; Ohsumi S; Hausheer FH
Support Care Cancer; 2009 Aug; 17(8):1071-80. PubMed ID: 19089463
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
